· L'USAMRIID (United States Army Medical Research Institute of Infectious Diseases) evaluated DNV3681 against Bacillus anthracis that triggers anthrax and Francisella tularensis that triggers tularemia or rabbit fever, both bacteria being classified in the "high priority" category of biothreat agents
· DNV3681 demonstrated a superior in vitro efficacy compared to Ciprofloxacin which is the product of reference when exposed to Bacillus anthracis
· These data will be presented during ASM 2019 which will take place from the 20th to the 24th of June 2019 in San Francisco
· DNV3681 is the active molecule of DNV3837, developed in parallel by DEINOVE as a potential treatment for gastrointestinal infections caused by Clostridium difficile
DEINOVE (Euronext Growth Paris: ALDEI), a French biotech company that uses a disruptive approach to develop innovative antibiotics and bio-based active ingredients for cosmetics and nutrition, announces that Maj. Steven Zumbrun, Ph.D. from the United States Army Medical Research Institute of Infectious Diseases (USAMRIID) will present, at the annual congress of the American Society of Microbiology, results of the DNV3681 in vitro evaluation against Bacillus anthracis and Francisella tularensis:
SESSION P442 - AAR08 - New Antimicrobial Agents (pre-Phase 2): Novel Inhibitors of Protein and DNA Synthesis - Poster AAR-789 - DNV3681 is a Novel Quinolonyl-Oxazolidinone Antibacterial with Potent Activity against Biothreat Pathogens. S. D. Zumbrun, S. A. Halasohoris, L. L. Miller, L. M. Pysz & G. Gaudriault
Bacillus anthracis and Francisella tularensis are classified as two of the most dangerous possible biological weapons. Such research could lead to another application for DNV3681, the active molecule of DNV3837 currently being tested by DEINOVE as a treatment targeting Clostridium difficile, the bacterium that causes gastrointestinal infections.
The standard of care against Bacillus anthracis and Francisella tularensis is currently Ciprofloxacin, a synthetic large spectrum antibiotic from the fluoroquinolones' family. Several pathogenic bacterial species have already developed a resistance against this family of antibiotics and the long treatment needed for Post-exposure Prophylaxis of Anthrax very often triggers a major intestinal microbiota imbalance leading to likely Clostridioides difficile infections. Therefore, there is an urgency to make efficient and validated alternatives available.
The fact that the DNV3681 is precisely very active against both Bacillus anthracis and Clostridioides difficile makes it an ideal candidate to fulfill that need.